| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | David Price | Q37830471 |
| Eugene R Bleecker | Q65560413 | ||
| P2093 | author name string | Arnaud Bourdin | |
| Trung N Tran | |||
| Marianna Alacqua | |||
| Andrew N Menzies-Gow | |||
| Amber L Martin | |||
| Stephen Sweet | |||
| P2860 | cites work | Higher prevalence of obesity among children with asthma. | Q35948136 |
| Factors associated with systemic hypertension in asthma | Q35976963 | ||
| Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry | Q36110425 | ||
| The association between gastro-oesophageal reflux disease and asthma: a systematic review | Q36172860 | ||
| CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids | Q36410606 | ||
| Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study | Q36603266 | ||
| Asthma genetics and personalised medicine | Q36622292 | ||
| Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency | Q36828092 | ||
| Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma | Q36886258 | ||
| Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study | Q36924944 | ||
| Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations | Q37137128 | ||
| Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). | Q37177646 | ||
| Postoperative Adverse Outcomes in Patients With Asthma: A Nationwide Population-based Cohort Study | Q37204982 | ||
| Electronic health record-based assessment of oral corticosteroid use in a population of primary care patients with asthma: an observational study | Q37355942 | ||
| Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis | Q37381144 | ||
| Statin exposure is associated with decreased asthma-related emergency department visits and oral corticosteroid use. | Q37393675 | ||
| Subacute lack of asthma control as a predictor of subsequent acute asthma exacerbation in a managed care population | Q37690684 | ||
| Relationship between short-acting β2-adrenergic agonist use and healthcare costs | Q37846692 | ||
| Concomitant asthma medication use by patients receiving omalizumab 2003-2008. | Q37957149 | ||
| International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma | Q38171268 | ||
| The changing face of severe childhood asthma: a comparison of two cohorts of children evaluated at National Jewish Health over the past 20 years | Q38203409 | ||
| Can HLA-DRB4 Help to Identify Asthmatic Patients at Risk of Churg-Strauss Syndrome? | Q38421813 | ||
| Differential connectivity of gene regulatory networks distinguishes corticosteroid response in asthma | Q38430805 | ||
| Asthma Pharmacogenomics: 2015 Update | Q38542847 | ||
| More Than a Decade Follow-up in Severe or Difficult-to-Treat Asthma: TENOR II. | Q38629999 | ||
| Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France | Q38650895 | ||
| Comparison of the Proportion and Healthcare Utilisation of Adult Patients with Uncontrolled Severe Asthma versus Non-Severe Asthma Seen in a Southeast Asian Hospital-Based Respiratory Specialist Clinic | Q38667145 | ||
| Asthma medication use among adults with current asthma by work-related asthma status, Asthma Call-back Survey, 29 states, 2012-2013. | Q38681057 | ||
| Oral corticosteroid exposure and adverse effects in asthmatic patients | Q38689383 | ||
| Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma. | Q38755623 | ||
| Oral Corticosteroid Prescribing for Children With Asthma in a Medicaid Managed Care Program | Q38756463 | ||
| Different oral corticosteroid regimens for acute asthma | Q24185767 | ||
| Risk factors for asthma-related healthcare use: longitudinal analysis using the NHI claims database in a Korean asthma cohort | Q28544969 | ||
| Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids | Q28943401 | ||
| Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma | Q30275238 | ||
| Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations | Q30276073 | ||
| Asthma drug ratios and exacerbations: claims data from universal health coverage systems | Q30813220 | ||
| Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice | Q31038671 | ||
| The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. | Q33608765 | ||
| Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. | Q33624579 | ||
| Effects of a german asthma disease management program using sickness fund claims data | Q33633296 | ||
| Body mass index and comorbidities in adult severe asthmatics | Q33758699 | ||
| The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis | Q33837390 | ||
| The relationship between asthma and depression in primary care patients: a historical cohort and nested case control study | Q33941236 | ||
| Corticosteroids in the treatment of acute asthma | Q34197151 | ||
| Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review | Q34224379 | ||
| Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma | Q34557028 | ||
| Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide | Q34982235 | ||
| Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational study | Q35022943 | ||
| Safety of investigative bronchoscopy in the Severe Asthma Research Program | Q35146224 | ||
| Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study | Q35216441 | ||
| Effect of catastrophic wildfires on asthmatic outcomes in obese children: breathing fire | Q35286683 | ||
| Prescribed therapy for asthma: therapeutic ratios and outcomes | Q35534302 | ||
| Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis | Q35637447 | ||
| Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study | Q35834906 | ||
| Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study | Q35889211 | ||
| Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry | Q35906666 | ||
| Inappropriate prescribing of combination inhalers in Northern Ireland: retrospective cross-sectional cohort study of prescribing practice in primary care. | Q46027040 | ||
| Association between consistent omalizumab treatment and asthma control | Q46135531 | ||
| Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts | Q46202830 | ||
| Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years | Q46747559 | ||
| Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations | Q46774354 | ||
| Current status of asthma care in South Korea: nationwide the Health Insurance Review and Assessment Service database | Q47161035 | ||
| RItA: The Italian severe/uncontrolled asthma registry. | Q47598081 | ||
| Controversies and opportunities in severe asthma | Q47670536 | ||
| Comorbidities in Difficult-to-Control Asthma | Q47689833 | ||
| Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization | Q47691423 | ||
| Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio | Q47691433 | ||
| The clinical role of fractional exhaled nitric oxide in asthma control | Q47720473 | ||
| Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review | Q47749614 | ||
| The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis | Q47769040 | ||
| Severe and Difficult-to-Treat Asthma in Adults | Q47848891 | ||
| Mepolizumab treatment in patients with severe eosinophilic asthma | Q48065984 | ||
| The effects of bariatric surgery on asthma severity | Q48363086 | ||
| High-altitude treatment in atopic and nonatopic patients with severe asthma | Q48464336 | ||
| Can the response to Omalizumab be influenced by treatment duration? A real-life study. | Q50794278 | ||
| Long-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. | Q51247188 | ||
| Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. | Q51330127 | ||
| Predictors of frequent exacerbations in (ex)smoking and never smoking adults with severe asthma. | Q51463089 | ||
| Morbidity associated with oral corticosteroids in patients with severe asthma. | Q51545298 | ||
| Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. | Q51699006 | ||
| Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. | Q52727450 | ||
| Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. | Q55004171 | ||
| Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. | Q55374314 | ||
| Use of oral corticosteroids in the United Kingdom | Q57086781 | ||
| Use of inhaled corticosteroids and the risk of tuberculosis | Q57213532 | ||
| Adrenal responses to a low-dose short synacthen test in children with asthma | Q57302531 | ||
| Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma | Q57313580 | ||
| Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study | Q58694343 | ||
| A Charter to Improve Patient Care in Severe Asthma | Q58764055 | ||
| Application of Multicategory Exposure Marginal Structural Models to Investigate the Association between Long-Acting Beta-Agonists and Prescribing of Oral Corticosteroids for Asthma Exacerbations in the Clinical Practice Research Datalink | Q60438361 | ||
| Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma | Q62075724 | ||
| Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature | Q64122347 | ||
| The pharmacists’ potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma | Q64135102 | ||
| Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. A controlled trial by the British Thoracic and Tuberculosis Association | Q66705462 | ||
| The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care | Q84920205 | ||
| Risk of deep vein thrombosis and pulmonary embolism in asthma | Q85758764 | ||
| Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalatio | Q85887391 | ||
| Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey | Q86452627 | ||
| Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients | Q86639478 | ||
| Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy | Q86999307 | ||
| Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients | Q87514611 | ||
| Relative exposure to controller therapy and asthma exacerbations: a validation study in community pharmacies | Q88113035 | ||
| Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma | Q88755312 | ||
| Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma | Q89484943 | ||
| Impact of asthmatic control status on serum cystatin C concentrations | Q95812256 | ||
| Real-life Efficacy of Omalizumab After 9 Years of Follow-up. | Q38789811 | ||
| Predictors of future exacerbation risk in patients with asthma. | Q38834113 | ||
| Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma | Q38844831 | ||
| Measuring the cost of poor asthma control and exacerbations | Q38861286 | ||
| Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils | Q38980122 | ||
| Intervention to reduce unnecessary dispensing of short-acting {beta}-agonists in patients with asthma | Q39289487 | ||
| Burden of systemic glucocorticoid-related complications in severe asthma | Q39391610 | ||
| Exploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire | Q39405147 | ||
| Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Q39408906 | ||
| Asthma control and management changes in Japan: questionnaire survey | Q39636426 | ||
| Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. | Q39650450 | ||
| Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma | Q39652108 | ||
| Asthma Controller Medication Adherence, Risk of Exacerbation, and Use of Rescue Agents Among Texas Medicaid Patients with Persistent Asthma. | Q40199154 | ||
| Acute and chronic systemic corticosteroid-related complications in patients with severe asthma | Q40491257 | ||
| Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease | Q40537192 | ||
| Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort | Q40552098 | ||
| Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. | Q40800790 | ||
| Persistence with inhaled corticosteroids reduces the risk of exacerbation among adults with asthma: A real-world investigation | Q40809434 | ||
| Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005-2011. | Q40847170 | ||
| Prospective Study on the Relationship of Obesity to Asthma Impairment and Risk. | Q40938863 | ||
| Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma | Q41044750 | ||
| Dedicated severe asthma services improve health-care use and quality of life | Q41193431 | ||
| Association of Serum Lipids and Obstructive Lung Disease in Hispanic/Latino Adults of Diverse Backgrounds | Q41675310 | ||
| Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). | Q41746887 | ||
| The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. | Q42601501 | ||
| Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy | Q43037756 | ||
| Prevalence of bronchiectasis in asthma according to oral steroid requirement: influence of immunoglobulin levels. | Q43266463 | ||
| Care of asthma patients in relation to guidelines | Q43417500 | ||
| The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. | Q43680825 | ||
| Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma | Q43943953 | ||
| Cost and health care utilization in patients with asthma and high oral corticosteroid use. | Q44572323 | ||
| Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD). | Q44794033 | ||
| Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis | Q44944967 | ||
| Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Q45297326 | ||
| Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database. | Q45297463 | ||
| Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: a population-based study | Q45347692 | ||
| Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States | Q45428030 | ||
| P433 | issue | 3 | |
| P921 | main subject | asthma | Q35869 |
| systematic review | Q1504425 | ||
| literature review | Q2412849 | ||
| P304 | page(s) | 276-293 | |
| P577 | publication date | 2020-02-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management | |
| P478 | volume | 201 |
| Q99357044 | Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial |
| Q100395872 | Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) |
| Q90280113 | Oral Corticosteroid Prescription Patterns for Asthma in France, Germany, Italy, and the United Kingdom |
Search more.